Impressive early results for Vertex’s potentially curative stem cell diabetes therapy
A cure for Type 1 diabetes has come one step closer as Vertex reports 90-day results for its synthetic insulin cell therapy.
Markets
Indian pharma deals landscape shaped by Covid-19
The number of deals made in the Indian pharma market increased by 22% from 2019...
Oral Covid-19 drugs: Merck’s molnupiravir and its closest rivals
With Merck and Ridgeback revealing their topline Phase III data, the stage is set for...
Regulatory roundup: GSK’s Zejula hampered by Phase II suspension
BMS’s and Cytokinetics’ respective CVD drugs are among other assets reviewed by GlobalData’s Investigative News...
4D Pharma Q&A: the potential of gut bacteria in cancer and beyond
4D Pharma CEO Duncan Peyton discusses the company’s work on bacteria-based therapies for cancer, neurodegeneration...
Oral JAK inhibitors unlikely to be totally shut out in eczema by black box warning
Dermatologists point to several uptake openings for JAK inhibitors in moderate-to-severe eczema despite highly publicized side effect concerns.
Clover Biopharmaceuticals’ Covid-19 jab could help boost global vaccine supply
The clinical-stage company has announced that its Covid-19 vaccine candidate, SCB-2019, is 67% effective against the virus.
Waning Covid-19 vaccine efficacy: what does the data show?
While Covid-19 vaccines’ protection does appear to wane, most experts agree that universal booster rollouts aren’t needed yet.
Regulatory roundup: BMS’s T lymphocyte immunotherapy tripped by lung cancer trial termination
Sanofi’s pemphigus asset, Artios solid tumor trial among recent events reviewed by GlobalData’s Investigative News team.
Regulatory roundup: Ology, MaxCyte make moves in women’s cancer with divergent approval chances
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
Ferring draws closer to a microbiome breakthrough
Ferring and subsidiary Rebiotix are developing a microbiota-based live biotherapeutic, RBX2660, against recurrent C. diff.
